Heme-artemisinin activation complex (Heme-ART)

The heme-artemisinin activation complex is the critical biochemical intermediate responsible for the potent antimalarial activity of artemisinin and its derivatives. These drugs are sesquiterpene lactone prodrugs that require activation by the ferrous iron found in free heme, a byproduct of hemoglobin degradation within the malaria parasite's acidic food vacuole (O'Neill et al., 2010; PMID: 20443557). The reaction between heme and the drug's essential endoperoxide bridge generates short-lived, highly reactive carbon-centered radicals. These radicals act as 'molecular grenades,' alkylating a broad spectrum of essential parasite targets, including proteins involved in calcium signaling (e.g., PfATP6) and various metabolic pathways (Wang et al., 2015; PMID: 26699530). This unique, heme-dependent mechanism ensures that the drug's lethal effects are concentrated within infected red blood cells, providing a high therapeutic index against Plasmodium species. However, the emergence of resistance linked to mutations in the Kelch 13 protein, which affects the parasite's stress response and drug activation environment, poses a significant threat to the continued efficacy of this drug class.

Other names

Heme-artemisinin adductFerriprotoporphyrin IX-artemisinin complexHeme-activated artemisininArtemisinin-heme complex

Artemisinin derivatives act as prodrugs that are activated by the ferrous iron (Fe2+) within free heme (ferriprotoporphyrin IX), which is released during the digestion of host hemoglobin by malaria parasites. This interaction triggers the reductive cleavage of the drug's 1,2,4-trioxane endoperoxide bridge, resulting in the formation of highly reactive carbon-centered free radicals. These radicals then covalently bind to and damage various parasite proteins and lipids, leading to cellular dysfunction and parasite death (Meshnick, 2002; PMID: 12165161).